6461-04-7

Basic information

• Product Name: H-D-GLU(OME)-OH
• Synonyms: H-D-GLU(ME)-OH;H-D-GLU(OME)-OH;D-Glutamic acid γ-methyl ester≥ 99% (HPLC);D-Glutamicacidg-methylester;(R)-2-Aminoglutaric acid 5-methyl ester;(2R)-2-aMino-5-Methoxy-5-oxo-pentanoate;4(R)-Carboxy-4-aminobutanoic acid methyl ester;gamma-Methyl D-glutamate
• CAS NO: 6461-04-7
• Molecular Formula: C₆H₁₁NO₄
• Molecular Weight: 161.16
• EINECS: 229-276-2
• Mol File: 6461-04-7.mol
• Article Data: 11

Chemical Properties

• Melting Point: 175-176℃
• Boiling Point: 316.1 °C at 760 mmHg
• Flash Point: 145 °C
• Appearance: /
• Density: 1.242 g/cm³
• Vapor Pressure: 8.95E-05mmHg at 25°C
• Refractive Index: 1.477
• Storage Temp.: 2-8°C
• PKA: 2.18±0.10(Predicted)
• CAS DataBase Reference: H-D-GLU(OME)-OH(CAS DataBase Reference)
• NIST Chemistry Reference: H-D-GLU(OME)-OH(6461-04-7)
• EPA Substance Registry System: H-D-GLU(OME)-OH(6461-04-7)

Safety Data

• Hazardous Substances Data: 6461-04-7(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Uses

D-Glutamic acid 5-methyl ester is a protected form of D-Glutamic acid (G596965). D-Glutamic acid is an unnatural isomer of L-Glutamic acid (G596960), and is found in bacterial cell wall peptidoglycan of gram-positive and gram-negative bacteria. D-Glutamic acid also occurs as poly-gamma-Glutamic acid, which is a weak immunogen but is capable of acting as a hapten (a small molecule that induces the production of antibodies, as well as binding to them).

InChI:InChI=1/C6H11NO4/c1-11-5(8)3-2-4(7)6(9)10/h4H,2-3,7H2,1H3,(H,9,10)/t4-/m1/s1

Upstream product

• 6893-26-1 D-Glutamic acid 
• 1499-55-4 L-glutamic acid 5-methyl ester 
• 75-77-4 chloro-trimethyl-silane 
• 5817-08-3 Acetyl-D,L-glutaminsaeure 
• 75-36-5 acetyl chloride 
• 67-56-1 methanol 
• 3343-28-0 N-phthaloylglutamic acid anhydride 
• 617-65-2 Glutamic acid 
• 138036-14-3 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-5-methoxy-5-oxopentanoic acid 

Downstream Products

• 45214-91-3 N-α-(tert-butoxycarbonyl)-D-glutamic acid γ-methyl ester 
• 905291-68-1 (2R)-2-[(4-iodobenzoyl)amino]-5-methoxy-5-oxopentanoic acid 
• 5959-95-5 D-Glutamin 
• 1159764-39-2 (R)-2-diphenylacetylamino-pentanedioic acid 5-methyl ester 
• 70206-54-1 N-Benzoyl-D,L-glutamic acid γ-methyl ester 
• 27025-27-0 N-Z-D-Glu-D-Glu-γ.γ'-dimethylester 
• 27126-81-4 N-Z-L-Glu-D-Glu-γ.γ'-dimethylester 
• 1323405-59-9 3-(4-((4-((4-methylpiperazin-1-yl)methyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 
• 1323407-86-8 3-[4-[[4-(bromomethyl)phenyl]methoxy]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione 
• 112159-16-7 2-((tert-butoxycarbonyl)amino)-5-methoxy-5-oxopentanoic acid 
• 138036-14-3 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-5-methoxy-5-oxopentanoic acid 

Relevant articles and documents

Synthesis of Carbapenems Containing Peptidoglycan Mimetics and Inhibition of the Cross-Linking Activity of a Transpeptidase of l,d Specificity

The carbapenem class of β-lactams has been optimized against Gram-negative bacteria producing extended-spectrum β-lactamases by introducing substituents at position C2. Carbapenems are currently investigated for the treatment of tuberculosis as these drugs are potent covalent inhibitors of l,d-transpeptidases involved in mycobacterial cell wall assembly. The optimization of carbapenems for inactivation of these unusual targets is sought herein by exploiting the nucleophilicity of the C8 hydroxyl group to introduce chemical diversity. As β-lactams are structure analogs of peptidoglycan precursors, the substituents were chosen to increase similarity between the drug and the substrate. Fourteen peptido-carbapenems were efficiently synthesized. They were more effective than the reference drug, meropenem, owing to the positive impact of a phenethylthio substituent introduced at position C2 but the peptidomimetics added at position C8 did not further improve the activity. Thus, position C8 can be modified to modulate the pharmacokinetic properties of highly efficient carbapenems.

Method for preparing azaindole compound

The invention provides a method for preparing an azaindole compound represented by a formula (I). According to the method, natural amino acid is used as a starting material to synthesize an intermediate defined in the specification, the intermediate reacts with 2-(N-tert-butyloxycarbonylamino)-3-methylpyridine in the presence of an organic alkali to obtain an intermediate defined in the specification, a protecting group is removed from the intermediate under an acidic condition, cyclization is performed to obtain an azaindole compound defined in the specification, and cyclization is performedthrough alcohol activating or a Mitsunobu reaction to obtain a compound represented by the formula (I). According to the method provided by the invention, natural amino acid is used as a starting material, so that complex processes such as chiral auxiliary synthesis, chiral resolution or introduction of chiral amino by enzyme catalytic reaction, and the like are avoided, the cost is greatly reduced, and the method is suitable for industrial large-scale production.

ANTIPROLIFERATIVE COMPOUNDS AND BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 FOR COMBINED USE

Provided herein is are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l- oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof and a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3e (CD3) provided herein, in treating, preventing or managing multiple myeloma.